open access

Vol 7, No 1 (2004)
Published online: 2004-01-22
Submitted: 2012-01-23
Get Citation

Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer

Roussanka D. Kovatcheva, Tatjana D. Hadjieva, Georgi G. Kirilov, Bojan S. Lozanov
Nucl. Med. Rev 2004;7(1):13-19.

open access

Vol 7, No 1 (2004)
Published online: 2004-01-22
Submitted: 2012-01-23

Abstract

BACKGROUND: Recombinant human TSH (rhTSH) has been developed to facilitate the follow-up for persistent or recurrent differentiated thyroid cancer (DTC), avoiding the hypothyroid symptoms after the withdrawal of Levothyroxine (L-T4 ) suppressive therapy.
MATERIAL AND METHODS: To analyse the effect of rhTSH in providing stimulation of radioiodine uptake (RAIU) for the ablation of thyroid remnant and/or malignant thyroid tissue in patients with metastatic DTC. Ten subjects (4 women, 6 men), mean age 53 years, with DTC (7 papillary, 2 follicular and 1 Hürthle-cell), requiring radioiodine therapy (RIT) were studied. Nine of them had a positive diagnostic whole body scan (dWBS) or CT for thyroid remnant, lymph nodes and/or distant metastases. One patient with an invasive tall cell PTC had an increased serum Tg and a negative dWBS. Serum TSH was measured before and two days after the rhTSH injection. Thyroglobulin measurements were performed before the rhTSH administration, 3 and 6 months after RIT. There were no serious side effects of the rhTSH application.
RESULTS: Serum TSH after the rhTSH injection rose to 156.5 ± ± 60.9 mIU/L and induced RAIU in 8 out of 10 patients. Basal serum Tg was increased in 6 patients and decreased three months later in 2 of them. The post-therapy WBS (pthWBS) showed: 1) additional metastatic lesions in 3 patients with positive dWBS, 2) lung nodular metastases in 1 patient with negative dWBS, 3) similar image as the dWBS in 4 patients, 4) negative image in 1 patient with positive dWBS.
CONCLUSION: RhTSH is a safe and promising method for the stimulation of RAIU in patients with thyroid remnant and/or persistent or recurrent DTC, avoiding L-T4 withdrawal.

Abstract

BACKGROUND: Recombinant human TSH (rhTSH) has been developed to facilitate the follow-up for persistent or recurrent differentiated thyroid cancer (DTC), avoiding the hypothyroid symptoms after the withdrawal of Levothyroxine (L-T4 ) suppressive therapy.
MATERIAL AND METHODS: To analyse the effect of rhTSH in providing stimulation of radioiodine uptake (RAIU) for the ablation of thyroid remnant and/or malignant thyroid tissue in patients with metastatic DTC. Ten subjects (4 women, 6 men), mean age 53 years, with DTC (7 papillary, 2 follicular and 1 Hürthle-cell), requiring radioiodine therapy (RIT) were studied. Nine of them had a positive diagnostic whole body scan (dWBS) or CT for thyroid remnant, lymph nodes and/or distant metastases. One patient with an invasive tall cell PTC had an increased serum Tg and a negative dWBS. Serum TSH was measured before and two days after the rhTSH injection. Thyroglobulin measurements were performed before the rhTSH administration, 3 and 6 months after RIT. There were no serious side effects of the rhTSH application.
RESULTS: Serum TSH after the rhTSH injection rose to 156.5 ± ± 60.9 mIU/L and induced RAIU in 8 out of 10 patients. Basal serum Tg was increased in 6 patients and decreased three months later in 2 of them. The post-therapy WBS (pthWBS) showed: 1) additional metastatic lesions in 3 patients with positive dWBS, 2) lung nodular metastases in 1 patient with negative dWBS, 3) similar image as the dWBS in 4 patients, 4) negative image in 1 patient with positive dWBS.
CONCLUSION: RhTSH is a safe and promising method for the stimulation of RAIU in patients with thyroid remnant and/or persistent or recurrent DTC, avoiding L-T4 withdrawal.
Get Citation

Keywords

differentiated thyroid cancer; radioiodine therapy; recombinant human TSH

About this article
Title

Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer

Journal

Nuclear Medicine Review

Issue

Vol 7, No 1 (2004)

Pages

13-19

Published online

2004-01-22

Bibliographic record

Nucl. Med. Rev 2004;7(1):13-19.

Keywords

differentiated thyroid cancer
radioiodine therapy
recombinant human TSH

Authors

Roussanka D. Kovatcheva
Tatjana D. Hadjieva
Georgi G. Kirilov
Bojan S. Lozanov

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl